Tata India Pharma & Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹1,541 Cr

Expense Ratio

0.97%

ISIN

INF277K019A3

Minimum SIP

₹1,000

Exit Load

No Charges

Inception Date

28 Dec 2015

About this fund

Tata India Pharma & Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by Tata Mutual Fund. This fund has been in existence for 10 years and 8 months, having been launched on 28-Dec-15.
As of 27-Aug-26, it has a Net Asset Value (NAV) of ₹40.01, Assets Under Management (AUM) of 1541.42 Crores, and an expense ratio of 0.97%.

Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 13.89% since inception.
The fund's asset allocation comprises around 99.14% in equities, 0.00% in debts, and 0.86% in cash & cash equivalents.
You can start investing in Tata India Pharma & Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+11.39%

+17.81% (Cat Avg.)

3 Years

+21.23%

+21.74% (Cat Avg.)

5 Years

+15.43%

+15.00% (Cat Avg.)

10 Years

+15.33%

+14.83% (Cat Avg.)

Since Inception

+13.89%

— (Cat Avg.)

Portfolio Summaryas of 31st July 2026

Equity	₹1,528.18 Cr	99.14%
Others	₹13.24 Cr	0.86%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹132.4 Cr	8.59%
Divi's Laboratories Ltd	Equity	₹98 Cr	6.36%
HealthCare Global Enterprises Ltd	Equity	₹90.21 Cr	5.85%
Abbott India Ltd	Equity	₹86.82 Cr	5.63%
Rainbow Childrens Medicare Ltd	Equity	₹75.52 Cr	4.90%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹71.87 Cr	4.66%
Cipla Ltd	Equity	₹69.81 Cr	4.53%
Dr Reddy's Laboratories Ltd	Equity	₹65.48 Cr	4.25%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹62.78 Cr	4.07%
Apollo Hospitals Enterprise Ltd	Equity	₹60.18 Cr	3.90%
Bayer CropScience Ltd	Equity	₹50.31 Cr	3.26%
Fortis Healthcare Ltd	Equity	₹48.13 Cr	3.12%
Pfizer Ltd	Equity	₹47.12 Cr	3.06%
Mankind Pharma Ltd	Equity	₹46.53 Cr	3.02%
Syngene International Ltd	Equity	₹45.53 Cr	2.95%
Sai Life Sciences Ltd	Equity	₹44.52 Cr	2.89%
Lupin Ltd	Equity	₹40.76 Cr	2.64%
Alkem Laboratories Ltd	Equity	₹39.72 Cr	2.58%
Procter & Gamble Health Ltd	Equity	₹37.25 Cr	2.42%
FDC Ltd	Equity	₹36.84 Cr	2.39%
Dr. Lal PathLabs Ltd	Equity	₹33.5 Cr	2.17%
Global Health Ltd	Equity	₹32.88 Cr	2.13%
Concord Biotech Ltd	Equity	₹29.46 Cr	1.91%
Sumitomo Chemical India Ltd Ordinary Shares	Equity	₹24.49 Cr	1.59%
Ajanta Pharma Ltd	Equity	₹23.58 Cr	1.53%
Neuland Laboratories Ltd	Equity	₹19.3 Cr	1.25%
Gillette India Ltd	Equity	₹17.76 Cr	1.15%
Metropolis Healthcare Ltd	Equity	₹17.32 Cr	1.12%
Manipal Health Enterprises Ltd	Equity	₹14.96 Cr	0.97%
BASF India Ltd	Equity	₹14.9 Cr	0.97%
Jubilant Pharmova Ltd	Equity	₹12.73 Cr	0.83%
Dr Agarwal’s Health Care Ltd	Equity	₹10.29 Cr	0.67%
Cash / Net Current Asset	Cash	₹9.27 Cr	0.60%
Sanofi Consumer Healthcare India Ltd	Equity	₹8.47 Cr	0.55%
Biocon Ltd	Equity	₹7.98 Cr	0.52%
Zim Laboratories Ltd Ordinary Shares	Equity	₹7.13 Cr	0.46%
(I) Treps	Cash - Repurchase Agreement	₹3.97 Cr	0.26%
Sanofi India Ltd	Equity	₹3.53 Cr	0.23%
Anthem Biosciences Ltd	Equity	₹0.11 Cr	0.01%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹1,420.72 Cr	92.17%
Basic Materials	₹89.71 Cr	5.82%
Consumer Defensive	₹17.76 Cr	1.15%

Risk & Performance Ratios

Fund Managers

Rajat Srivastava

Since September 2024

Additional Scheme Detailsas of 31st July 2026

ISIN

INF277K019A3

Expense Ratio

0.97%

Exit Load

No Charges

Fund Size

₹1,541 Cr

Age

10 years 8 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

Nifty Pharma TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Invesco India Pharma and Healthcare Fund Regular Growth Very High Risk	-	0.0%	-	-
Invesco India Pharma and Healthcare Fund Direct Growth Very High Risk	-	0.0%	-	-
DSP Nifty Healthcare ETF Very High Risk	0.3%	-	₹18.04 Cr	15.5%
Groww BSE Hospitals ETF Very High Risk	0.5%	-	₹131.38 Cr	-
Mirae Asset Nifty 500 Healthcare ETF Very High Risk	0.1%	-	₹13.99 Cr	-
Bandhan Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹319.40 Cr	-
Bandhan Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹319.40 Cr	-
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.6%	1.0%	₹519.48 Cr	12.8%
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.1%	1.0%	₹519.48 Cr	10.8%
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.6%	1.0%	₹376.77 Cr	22.7%
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹376.77 Cr	24.8%
PGIM India Healthcare Fund Direct Growth Very High Risk	0.9%	0.0%	₹111.64 Cr	26.6%
PGIM India Healthcare Fund Regular Growth Very High Risk	2.5%	0.0%	₹111.64 Cr	24.4%
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.8%	0.0%	₹824.90 Cr	22.1%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	1.2%	0.0%	₹824.90 Cr	24.2%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹14.94 Cr	11.4%
Kotak Healthcare Fund Direct Growth Very High Risk	0.9%	0.0%	₹682.39 Cr	28.1%
Kotak Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹682.39 Cr	26.1%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.2%	1.0%	₹2939.98 Cr	26.1%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	1.1%	1.0%	₹2939.98 Cr	27.6%
Nippon India Pharma Fund Direct Growth Very High Risk	0.8%	1.0%	₹9279.11 Cr	13.2%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	2.1%	1.0%	₹6802.61 Cr	9.4%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	1.3%	1.0%	₹6802.61 Cr	10.3%
DSP Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹3639.29 Cr	18.0%
DSP Healthcare Fund Regular Growth Very High Risk	2.0%	0.0%	₹3639.29 Cr	16.5%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.4%	1.0%	₹97.66 Cr	18.4%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.7%	1.0%	₹97.66 Cr	16.9%
quant Healthcare Fund Direct Growth Very High Risk	1.5%	1.0%	₹397.15 Cr	25.2%
quant Healthcare Fund Regular Growth Very High Risk	3.1%	1.0%	₹397.15 Cr	23.2%
UTI Healthcare Fund Direct Growth Very High Risk	1.3%	1.0%	₹1370.92 Cr	18.3%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	1.0%	0.0%	₹5399.88 Cr	22.3%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	0.0%	₹1541.42 Cr	9.8%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	1.0%	0.0%	₹1541.42 Cr	11.4%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹235.16 Cr	15.6%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	2.0%	0.0%	₹5399.88 Cr	21.1%
Nippon India Pharma Fund Regular Growth Very High Risk	1.5%	1.0%	₹9279.11 Cr	12.2%
UTI Healthcare Fund Regular Growth Very High Risk	2.2%	1.0%	₹1370.92 Cr	17.2%
Axis NIFTY Healthcare ETF Very High Risk	0.4%	-	₹24.81 Cr	15.3%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹1691.41 Cr	22.5%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.6%	1.0%	₹3442.28 Cr	19.4%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹3442.28 Cr	21.1%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.7%	0.0%	₹262.84 Cr	12.8%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	1.0%	0.0%	₹262.84 Cr	14.9%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹82.10 Cr	15.5%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹1073.85 Cr	17.5%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹1073.85 Cr	19.1%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.4%	-	₹44.16 Cr	16.8%

About the AMC

Tata Mutual Fund

+91 22 6657 8282

https://www.tatamutualfund.com/

Total AUM

₹2,28,733 Cr

Address

Mafatlal Centre, 9th Floor, Mumbai, 400 021

Other Funds by Tata Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Tata Multi Sector Passive FOF Direct Growth Very High Risk	0.2%	0.0%	-	-
Titanium Equity Long-Short Fund Direct Growth Very High Risk	1.9%	1.0%	₹207.85 Cr	-
Tata BSE Multicap Consumption 50 30 20 Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹46.22 Cr	-
Titanium Hybrid Long-Short Fund Direct Growth Very High Risk	1.0%	1.0%	₹548.72 Cr	-
Tata Nifty Next 50 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹124.10 Cr	-
Tata Nifty Midcap 150 Index Fund Direct Growth Very High Risk	0.2%	0.0%	₹316.58 Cr	11.5%
Tata Income Plus Arbitrage Active FOF Direct Growth Moderate Risk	0.1%	0.0%	₹268.99 Cr	6.0%
Tata BSE Quality Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹58.02 Cr	5.5%
Tata Fixed Maturity Plan Series 61 Scheme D 91 Days Direct Growth Low to Moderate Risk	0.1%	0.0%	₹209.75 Cr	-
Tata BSE Select Business Groups Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹228.30 Cr	6.4%
Tata India Innovation Fund Direct Growth Very High Risk	0.9%	0.0%	₹1368.35 Cr	6.0%
Tata Nifty Capital Markets Index Fund Direct Growth Very High Risk	0.7%	0.0%	₹913.12 Cr	27.6%
Tata Nifty200 Alpha 30 Index Fund Direct Growth Very High Risk	0.9%	0.0%	₹198.02 Cr	9.9%
Tata Nifty India Tourism Index Fund Direct Growth Very High Risk	0.5%	0.0%	₹269.84 Cr	-14.3%
Tata Fixed Maturity Plan Series 61 Scheme C 91 Days Direct Growth Low to Moderate Risk	-	0.0%	-	-
TATA Nifty500 Multicap India Manufacturing 50:30:20 Index Fund Direct Growth Very High Risk	0.6%	0.0%	₹138.43 Cr	13.0%
Tata Nifty500 Multicap Infrastructure 50:30:20 Index Fund Direct Growth Very High Risk	0.6%	0.0%	₹79.33 Cr	6.0%
Tata Nifty Financial Services Index Fund Direct Growth Very High Risk	0.6%	0.0%	₹71.15 Cr	1.5%
Tata Nifty Auto Index Fund Direct Growth Very High Risk	0.5%	0.0%	₹105.99 Cr	14.5%
Tata Nifty MidSmall Healthcare Index Fund Direct Growth Very High Risk	0.6%	0.0%	₹207.04 Cr	19.3%
Tata Nifty Realty Index Fund Direct Growth Very High Risk	0.5%	0.0%	₹65.00 Cr	1.8%
Tata Fixed Maturity Plan Series 61 Scheme A - 91 Days Direct Growth Low to Moderate Risk	0.1%	-	-	-
Tata Fixed Maturity Plan Series 61 Scheme B 364 Days Direct Growth Low to Moderate Risk	-	0.0%	-	-
Tata Silver ETF Fund of Fund Direct Growth Very High Risk	0.2%	0.0%	₹1008.57 Cr	96.9%
Tata Gold ETF Fund of Fund Direct Growth High Risk	0.2%	0.0%	₹1389.17 Cr	53.9%
Tata Fixed Maturity Plan Series 56 Scheme G Direct Growth Low to Moderate Risk	-	0.0%	-	-
Tata Fixed Maturity Plan Series 56 Scheme H Direct Growth Low to Moderate Risk	-	0.0%	-	-
Tata Fixed Maturity Series E Direct Growth Low to Moderate Risk	-	0.0%	-	-
Tata Balanced Advantage Fund Direct Growth Very High Risk	0.7%	0.0%	₹8779.78 Cr	5.5%
Tata Ultra Short Term Fund Direct Growth Moderate Risk	0.3%	0.0%	₹6377.77 Cr	6.9%
Tata Business Cycle Fund Direct Growth Very High Risk	0.9%	0.0%	₹2633.73 Cr	5.9%
Tata Nifty India Digital ETF Fund of Fund Direct Growth Very High Risk	0.1%	1.0%	₹113.18 Cr	-3.2%
Tata Nifty SDL Plus AAA PSU Bond Dec 2027 60: 40 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹644.59 Cr	5.9%
Tata Floating Rate Fund Direct Growth Moderate Risk	0.3%	0.0%	₹121.44 Cr	6.8%
Tata Small Cap Fund Direct Growth Very High Risk	0.5%	0.0%	₹12695.77 Cr	0.1%
Tata Large & Mid Cap Fund Direct Growth Very High Risk	0.8%	0.0%	₹7900.58 Cr	-2.1%
Tata Mid Cap Growth Fund Direct Growth Very High Risk	0.8%	0.0%	₹6056.43 Cr	11.9%
Tata Hybrid Equity Fund Direct Growth Very High Risk	1.3%	0.0%	₹3930.21 Cr	4.1%
Tata Ethical Fund Direct Growth Very High Risk	0.8%	0.0%	₹3864.51 Cr	-3.2%
Tata Gilt Securities Fund Direct Growth Moderate Risk	0.3%	0.0%	₹878.43 Cr	6.0%
Tata Equity P/E Fund Direct Growth Very High Risk	1.1%	0.0%	₹8492.28 Cr	6.8%
Tata Infrastructure Fund Direct Growth Very High Risk	1.2%	0.0%	₹2071.90 Cr	9.1%
Tata Treasury Advantage Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹2239.61 Cr	6.4%
Tata Money Market Fund Direct Growth Moderate Risk	0.2%	0.0%	₹34138.15 Cr	6.6%
Tata Equity Savings Fund Direct Growth Moderate Risk	0.6%	0.0%	₹284.62 Cr	7.5%
Tata Young Citizens Fund Direct Growth Very High Risk	1.8%	1.0%	₹334.58 Cr	-6.3%
Tata Liquid Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹27602.85 Cr	6.5%
Tata Large Cap Fund Direct Growth Very High Risk	1.2%	0.0%	₹2783.80 Cr	5.2%
Tata Retirement Savings Moderate Fund Direct Growth Very High Risk	0.8%	1.0%	₹2217.96 Cr	10.2%
Tata Retirement Savings Conservative Fund Direct Growth Moderately High risk	1.1%	1.0%	₹168.88 Cr	6.6%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Dezerv

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of Tata India Pharma & Healthcare Fund Direct Growth?

The NAV of Tata India Pharma & Healthcare Fund Direct Growth, as of 27-Aug-2026, is ₹40.01.

What are the returns of Tata India Pharma & Healthcare Fund Direct Growth?

The fund has generated 11.39% over the last 1 year and 21.23% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of Tata India Pharma & Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 99.14% in equities, 0.00% in bonds, and 0.86% in cash and cash equivalents.

Who manages the Tata India Pharma & Healthcare Fund Direct Growth?

The fund managers responsible for Tata India Pharma & Healthcare Fund Direct Growth are:-

Rajat Srivastava

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

©2021-2026 Dezerv. All Rights Reserved

Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

Tata India Pharma & Healthcare Fund Direct Growth

Fund Overview